Cargando…
Viral mHealth
Thousands of mHealth applications are developed every year, but few of these spread or ‘go viral’. Even clinical applications that provide health benefits and social value often linger after an initial pilot phase. An examination of common hindrances in low-income countries suggests that more subsid...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645666/ https://www.ncbi.nlm.nih.gov/pubmed/28838304 http://dx.doi.org/10.1080/16549716.2017.1336006 |
_version_ | 1783271937470889984 |
---|---|
author | Fölster, Stefan |
author_facet | Fölster, Stefan |
author_sort | Fölster, Stefan |
collection | PubMed |
description | Thousands of mHealth applications are developed every year, but few of these spread or ‘go viral’. Even clinical applications that provide health benefits and social value often linger after an initial pilot phase. An examination of common hindrances in low-income countries suggests that more subsidies and education of health care personnel are insufficient solutions. Instead we propose better a priori screening of mHealth applications based on four criteria that may largely determine whether an mHealth application will spread. Further, we illustrate how using these criteria forms a good basis for involving ‘impact investors’ in the development of mHealth applications. This can reduce risks for public health care providers and increase the likelihood of success. |
format | Online Article Text |
id | pubmed-5645666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-56456662017-10-24 Viral mHealth Fölster, Stefan Glob Health Action Current Debate Thousands of mHealth applications are developed every year, but few of these spread or ‘go viral’. Even clinical applications that provide health benefits and social value often linger after an initial pilot phase. An examination of common hindrances in low-income countries suggests that more subsidies and education of health care personnel are insufficient solutions. Instead we propose better a priori screening of mHealth applications based on four criteria that may largely determine whether an mHealth application will spread. Further, we illustrate how using these criteria forms a good basis for involving ‘impact investors’ in the development of mHealth applications. This can reduce risks for public health care providers and increase the likelihood of success. Taylor & Francis 2017-08-25 /pmc/articles/PMC5645666/ /pubmed/28838304 http://dx.doi.org/10.1080/16549716.2017.1336006 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Current Debate Fölster, Stefan Viral mHealth |
title | Viral mHealth |
title_full | Viral mHealth |
title_fullStr | Viral mHealth |
title_full_unstemmed | Viral mHealth |
title_short | Viral mHealth |
title_sort | viral mhealth |
topic | Current Debate |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645666/ https://www.ncbi.nlm.nih.gov/pubmed/28838304 http://dx.doi.org/10.1080/16549716.2017.1336006 |
work_keys_str_mv | AT folsterstefan viralmhealth |